People who cease taking GLP-1 obesity drugs, which include semaglutide (Wegovy) and tirzepatide (Zepbound), typically regain an average of nearly a pound a month, ultimately gaining back all the weight they lost within two years, according to a review of 37 earlier studies
In some cases, results from large human trials are already in
Review of the STEP clinical trial programme reporting mean weight losses of 14.9% to 17.4% across STEP 1, 3, 4 and 8 in individuals with overweight or obesity without type 2 diabetes from baseline to week 68
Curr Opin Pharmacol (2020) 54:91101
But rapid, dramatic weight loss often leaves behind a common, frustrating issue: loose, sagging skin that no amount of diet or exercise can fix
High costs, as well as tolerability issues, remain considerable barriers to a more wide-ranging prescribing of these drugs 1